Boston Scientific (NYSE:BSX) unveiled new study results at the EuroPCR meeting in Paris today, touting the "excellent" safety and effectiveness of its Promus Element drug-eluting stents in small coronary vessels.
Boston Scientific
EuroPCR: Sapien win, promising post-approval results weigh in Edwards’ favor
Leerink Swann analysts saw promise in a pair of "tidbits" about Edwards Lifesciences’ (NYSE:EW) Sapien XT transcatheter aortic valve implantation system presented at the EuroPCR conference in Paris this week.
MassDevice.com +3 | The top 3 med-tech stories for May 15, 2012.
Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
If you read nothing else today, make sure you’re still in the know with MassDevice +3.
Boston Scientific’s Synergy bioabsorbable stent stands up to Promus Element
Boston Scientific’s (NYSE:BSX) next-generation semi-bioabsorbable drug-eluting stent proved as safe and effective in treating coronary artery lesions as its well-established Promus Element system, the company revealed at the the EuroPCR conference in Paris today.
Boston Scientific’s Innova peripheral stent débuts in Europe | Regulatory Roundup
Boston Scientific (NYSE:BSX) said it plans to get its Innova stent for peripheral artery disease on the market in the European Union "immediately" now that it’s won CE Mark approval there.
St. Jude Medical wins CE Mark, launches Enlightn renal denervation system | MassDevice.com On Call
MASSDEVICE ON CALL —St. Jude Medical (NYSE:STJ) landed CE Mark approval and announced commercial launch for its Enlightn renal denervation system as a treatment for hypertension.
Boston Scientific’s Lotus TAVI system minimizes leakage in early trial
Boston Scientific’s (NYSE:BSX) Lotus transcatheter aortic valve implantation system fared well in an early feasibility study in patients with severe symptomatic aortic stenosis who were to sick to undergo open-heart surgery.
HRS 2012 Roundup: Cameron Health, Topera Medical and Riata take center stage
MassDevice.com +7 | The top 7 med-tech stories for the week of May 7, 2012.
Say hello to MassDevice +7, a bite-sized view of the top seven med-tech stories of the week. This latest feature of MassDevice.com’s coverage highlights our seven biggest and most influential stories from the week’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
If you read nothing else this weekend, make sure you’re still in the know with MassDevice +7.
HRS 2012: Is Cameron Health’s ‘leadless’ ICD a niche product or a game-changer?
The so-called "leadless" implantable cardiac defibrillator made by Cameron Health made its debut at the Heart Rhythm Society’s annual meeting this week, generating considerable excitement among physicians here in Boston.
Two studies presented at the conference, 1 sponsored by Cameron Health to back its investigational device exemption application with the FDA and a 2nd, "real-world" evaluation of European patients, both showed that the subcutaneous ICD has comparable safety and effectiveness rates as more traditional transvenous ICDs.
HRS 2012: Boston Scientific’s Watchman as effective as Warfarin
A medical device made by Boston Scientific (NYSE:BSX) designed to trap blood clots in the heart could be an important tool for preventing stroke in high-risk atrial fibrillation patients, researchers said today at the annual Heart Rhythm Society meeting in Boston.